We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Express Scripts, Walgreens Tie Up to Cut Specialty Drug Price
Read MoreHide Full Article
In a bid to ensure availability of specialty brand drugs Express Scripts Holding Company and Walgreens Boots Alliance (WBA - Free Report) recently announced plans to expand their existing group purchasing efforts.
Since biosimilars have the potential to lower production costs, the move is considered to be a prudent and timely one.
ValoremRx Specialty Solutions, LLC, will assist the companies to carry out the move by helping pharmacies selling expensive drugs to simplify the global supply chain and lowering costs for patients and clients using the specialty pharmacies of Express Scripts (Accredo) and Walgreens.
Express Scripts Holding Company Price and Consensus
Express Scripts joined Walgreens Boots Alliance Development GmbH (“WBAD”) group in May 2017 through a wholly-owned subsidiary, Innovative Product Alignment, LLC.
Notably, WBAD, is a global group purchasing organization that sources and contracts generic pharmaceuticals on behalf of its members. The move made Innovative Product Alignment, a member of WBAD.
Rationale of the Move
Specialty medication include costly and complex drugs and are prescribed on a regular basis. The latest pact will improve Express Scripts’ supply chain and make these medicines, including biosimilars, affordable and accessible to patients.
Per a research conducted by RAND Corporation, biosimilars for arthritis and cancer, have the potential to yield billions in cost savings in the United States. It may lead to a $54 billion reduction in direct spending on biologic drugs between 2018 and 2027.
Promising Market
Per a study by SNS Research, approved biosimilars will account for nearly $22 billion revenues by the end of 2020. Regulatory efforts to reduce healthcare costs are likely to aid this growth.
Given the potential that the market holds, we believe the latest move by these two medical behemoths is a strategic and timely one.
Share Price Performance
Over a year, Express Scripts has outperformed the broader industry. The stock has returned 6.9% compared with the industry’s gain of 1.9%.
Centene’s projected long-term growth rate is 14.4%. The stock has returned 16.9% in the past six months.
Bioverativ has an expected long-term growth rate of 14%. The stock has returned a whopping 106.8% in the past three months.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Express Scripts, Walgreens Tie Up to Cut Specialty Drug Price
In a bid to ensure availability of specialty brand drugs Express Scripts Holding Company and Walgreens Boots Alliance (WBA - Free Report) recently announced plans to expand their existing group purchasing efforts.
Since biosimilars have the potential to lower production costs, the move is considered to be a prudent and timely one.
ValoremRx Specialty Solutions, LLC, will assist the companies to carry out the move by helping pharmacies selling expensive drugs to simplify the global supply chain and lowering costs for patients and clients using the specialty pharmacies of Express Scripts (Accredo) and Walgreens.
Express Scripts Holding Company Price and Consensus
Express Scripts Holding Company Price and Consensus | Express Scripts Holding Company Quote
Express Scripts joined Walgreens Boots Alliance Development GmbH (“WBAD”) group in May 2017 through a wholly-owned subsidiary, Innovative Product Alignment, LLC.
Notably, WBAD, is a global group purchasing organization that sources and contracts generic pharmaceuticals on behalf of its members. The move made Innovative Product Alignment, a member of WBAD.
Rationale of the Move
Specialty medication include costly and complex drugs and are prescribed on a regular basis. The latest pact will improve Express Scripts’ supply chain and make these medicines, including biosimilars, affordable and accessible to patients.
Per a research conducted by RAND Corporation, biosimilars for arthritis and cancer, have the potential to yield billions in cost savings in the United States. It may lead to a $54 billion reduction in direct spending on biologic drugs between 2018 and 2027.
Promising Market
Per a study by SNS Research, approved biosimilars will account for nearly $22 billion revenues by the end of 2020. Regulatory efforts to reduce healthcare costs are likely to aid this growth.
Given the potential that the market holds, we believe the latest move by these two medical behemoths is a strategic and timely one.
Share Price Performance
Over a year, Express Scripts has outperformed the broader industry. The stock has returned 6.9% compared with the industry’s gain of 1.9%.
Zacks Ranks & Other Stocks to Consider
Express Scripts carries a Zacks Rank #2 (Buy).
A few other top-ranked stocks in the broader medical space are Centene Corp. (CNC - Free Report) and Bioverativ Inc. . Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Centene’s projected long-term growth rate is 14.4%. The stock has returned 16.9% in the past six months.
Bioverativ has an expected long-term growth rate of 14%. The stock has returned a whopping 106.8% in the past three months.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>